2026-10-22 Corporate News
Neurosense Therapeutics (ticker NRSN) experienced a sharp decline in its share price over the 24‑hour period concluding at 05:29 AM Central Europe on Wednesday, 21 October 2026. The stock fell 13.19 %, bringing its current trading level to approximately USD 2.39 on major exchanges. With a circulating supply of 1.9 million shares, the company’s market capitalization stands at USD 5.7 million, and the volume traded in the last 24 hours reached USD 313.4 thousand.
Recent Performance Context
- Historical decline: At the end of the previous month, Neurosense had already traded 59.74 % lower, reflecting a broader downward trend.
- Moving average: The 200‑day simple moving average (SMA) is at USD 13.62, far above the current price, underscoring the depth of the recent slide.
- 52‑week range: The highest price achieved in the past year was USD 25.4 on 19 November 2025, while the 52‑week low—only USD 2.36—was recorded on 19 October 2026, indicating a volatile trading environment.
Comparative Stock Activity
Over the same 24‑hour window, five related stocks exhibited varied movements:
| Stock | Ticker | 24‑hr Change | Current Price | Market Cap | Additional Insight |
|---|---|---|---|---|---|
| Brainsway | BWAY.TA | +1.58 % | ILA 3,672 | ILA 491.3 million | Price‑earnings ratio: 52.92 |
| Maris‑Tech | MTEK | +15.49 % | USD 0.45 | USD 4.6 million | Significant rally |
| Rail Vision | RVSN | –1.35 % | USD 2.88 | USD 6.8 million | Modest decline |
| Silynxcom | SYNX | –4.87 % | USD 0.78 | USD 5 million | Minor downturn |
| Icecure Medical | ICCM | +1.89 % | USD 1.05 | USD 4.9 million | Small uptick |
These figures illustrate that while some peers experienced modest gains or losses, Neurosense’s fall remains the most pronounced among the group.
Company Overview
NeuroSense Therapeutics Ltd. is a clinical‑stage biopharmaceutical enterprise focused on developing therapeutics for amyotrophic lateral sclerosis (ALS) and other neurodegenerative disorders. Operating on a global scale, the company aims to provide innovative treatments to patients worldwide. For further details, prospective investors and stakeholders can visit the company’s website at www.neurosense-tx.com . Neurosense is listed on the Nasdaq stock exchange and continues to pursue research and development milestones in its quest to address unmet medical needs in neurology.
The information presented here reflects market activity as of the specified date and time and is intended for general informational purposes only.
